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Background: Pain is one of the most important domains affecting health-related quality of life (HRQoL) in patients
with psoriatic arthritis (PsA). Secukinumab has demonstrated rapid and sustained improvements in signs and
symptoms, including HRQoL, among patients with active PsA. This analysis evaluates the effect of secukinumab on
patient-reported pain in PsA through 104 weeks of treatment.
Methods: Pain was assessed through week 104 using clinically relevant measures, including change from baseline
in a pain visual analog scale (VAS) and Short Form-36 (SF-36) bodily domain scores; proportion of patients reporting
improvements equal to or better than minimum clinically meaningful differences in the pain VAS and SF-36 bodily
pain domain scores; and proportion of patients with no, moderate, or extreme pain/discomfort measured by
the EuroQoL 5-Dimension 3-Level Questionnaire (EQ-5D-3 L) pain item scores. Correlations of pain measures
were analyzed using Pearson’s correlation coefficient. Pre-specified analyses of TNF-naïve patients and patients
who stopped TNF-inhibitors (TNFis) due to inadequate responses or safety/tolerability (TNF-IR patients) were
performed using “as-observed data.”
Results: Mean improvements from baseline in pain VAS scores were greater with secukinumab versus placebo by
week 3 (− 16.9; P < 0.0001 with secukinumab 300 mg and − 12.6; P < 0.05 with secukinumab 150 mg) and sustained
through week 104. SF-36 bodily pain domain scores were significantly greater with 300 mg secukinumab and
secukinumab 150 mg versus placebo by week 4 (16.2 and 16.3, respectively; P < 0.0001 for both), and these
changes were maintained through week 104. With both secukinumab 300 mg and secukinumab 150 mg,
improvements equal to or better than the minimum clinically meaningful differences in pain VAS and SF-36 bodily pain
were significant versus placebo at week 3 and week 4, respectively. At week 4, 15%, 9%, and 5% of patients receiving
secukinumab 300 mg, secukinumab 150 mg, and placebo, respectively, reported “no pain/discomfort” measured by
EQ-5D-3 L; these proportions increased to week 104 with both secukinumab doses. Similarly, improvements in pain
measures were significant in both TNF-naïve and TNF-IR patients.
Conclusion: Secukinumab provided rapid and sustained pain relief in PsA over 2 years of treatment. Improvements in
pain were reported regardless of prior exposure to TNFis.
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Psoriatic arthritis (PsA) is a chronic progressive, clinic-
ally heterogeneous inflammatory arthritis that can mani-
fest as peripheral arthritis, axial disease, enthesitis,
dactylitis, and psoriasis of the skin/nails [1, 2]. The dis-
ease burden of PsA, taking into account patient-reported
outcomes and disease activity measures, is similar to the
burden of rheumatoid arthritis and axial spondyloarthri-
tis [3]. A recent analysis from the population-based
Multinational Assessment of Psoriasis and Psoriatic Arth-
ritis (MAPP) found that 88% of patients questioned had
ongoing joint pain or soreness, and 60% reported > 4
affected joints [4]. The most common locations for joint
pain were the knee (41%) followed by finger (26%), hip
(19%), ankle (19%), back (18%), and wrist (16%) [4].
The combination of ongoing pain, fatigue, physical im-
pairment, and anxiety likely influence the impact of PsA
and reduce health-related quality of life (HRQoL) [5]. Spe-
cifically, patients with PsA have impaired HRQoL charac-
terized by poor physical functioning and engagement in
daily activities, and pain [6]. In a European League Against
Rheumatism (EULAR) initiative to develop and validate
the Psoriatic Arthritis Impact of Disease questionnaire
(PsAID), patients with PsA identified pain as the most im-
portant health domain affecting HRQoL [7]. Additionally,
arthritis or joint pain causes a significant economic impact
that results in US$6773 greater costs compared to individ-
uals without either [8]. Pain poses an important clinical
challenge in the treatment of PsA. In a population-based
survey, rheumatologists and dermatologists considered
joint pain or swelling to be the critical factor contributing
to the severity of PsA [9]. Treatment criteria, scoring indi-
ces, and clinical trial domains further reflect the importance
of pain in PsA. The Group for Research and Assessment of
Psoriasis and Psoriatic Arthritis (GRAPPA) includes pain as
an important factor to examine when treating patients with
PsA [10]. A patient pain visual analog scale (VAS)
score ≤ 15 is one of seven critical criteria for determining
minimal disease activity in PsA [11]. Finally, at the Outcome
Measures in Rheumatology (OMERACT) 2016 conference,
pain was endorsed as part of a core set of domains recom-
mended for study in randomized controlled trials (RCTs)
and longitudinal observational studies (LOS) in PsA [12].
Secukinumab, a fully human monoclonal antibody
(mAb) that selectively neutralizes interleukin (IL)-17A,
has been shown to have significant efficacy in the treat-
ment of moderate-to-severe psoriasis and active PsA,
demonstrating rapid onset of action and sustained re-
sponses with a consistent safety profile [13, 14]. Since
2015 in the European Union and 2016 in the USA,
secukinumab 300 mg and 150 mg have been approved
for the treatment of active PsA. In the phase-3 FUTURE
2 study, secukinumab was effective in treating patients
not previously exposed (TNF-naïve patients) to TNF-αinhibitors (TNFis) and patients who stopped using up to
three previous TNFis due to inadequate responses or for
safety/tolerability reasons (TNF-IR patients) [15]. Over
2 years, secukinumab was shown to exhibit rapid and
sustained improvements in the signs and symptoms of
active PsA, to inhibit radiographic progression, and to
improve HRQoL [16, 17]. This post-hoc analysis of
FUTURE 2 examines the effect of secukinumab on
patient-reported pain in PsA over 104 weeks.
Methods
Details of FUTURE 2 (NCT01752634), an ongoing, mul-
ticenter RCT, have been reported previously [15] and
will be briefly summarized here.
Patients
FUTURE 2 was conducted at 76 centers throughout Asia,
Australia, Europe, and North America, in accordance with
the principles of the Declaration of Helsinki, and all cen-
ters received approval from independent ethics commit-
tees or institutional review boards. Patients included in
this trial were aged ≥ 18 years, met the Classification
criteria for Psoriatic Arthritis (CASPAR), had ≥ 3 tender
and ≥ 3 swollen joints despite treatment with non-steroidal
anti-inflammatory drugs (NSAIDs), disease-modifying
anti-rheumatic drugs (DMARDs), or TNFis. Patients who
had not responded adequately to up to three treatments
with TNFis were eligible for inclusion.
A TNFi wash-out period ≥ 4 weeks prior to
randomization was mandatory. Patients on concomitant
oral corticosteroids who received a stable dose for ≥ 2 weeks
prior to randomization (≤ 10 mg/day) and patients who
were on methotrexate and received a stable dose for
≥ 4 weeks prior to randomization (≤ 25 mg/week) were
allowed throughout the trial. Patients were excluded from
the study for previous use of biologic agents other than
TNFis; active inflammatory diseases other than PsA; active
infection within 2 weeks prior to randomization or a history
of chronic, ongoing, or recurrent infections; pregnancy; or
malignancy within the past 5 years, with the exception of
basal cell carcinoma or actinic keratosis, in-situ cervical
cancer, or non-invasive malignant colon polyps.
Study design and assessments
Patients were randomized 1:1:1:1 to receive subcutane-
ous secukinumab 300 mg, secukinumab 150 mg,
secukinumab 75 mg, or placebo at baseline, weeks 1, 2,
and 3, and then every 4 weeks from week 4. At week 16,
patients were classified as responders (≥ 20% improve-
ment from baseline in tender and swollen joint counts) or
non-responders. Placebo-treated patients were randomly
assigned again in a 1:1 ratio to receive subcutaneous
secukinumab 300 mg or 150 mg every 4 weeks from week
16 (non-responders) or week 24 (responders). This study
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until week 104.
Pain was assessed through week 104 by the mean
change from baseline in the pain VAS and Short Form-36
(SF-36) bodily pain domain scores; proportion of patients
reporting improvements equal to or better than the mini-
mum clinically meaningful difference (MCID) in the pain
VAS score (mean change from baseline ≥ 20%) [18]; pro-
portion of patients reporting improvements equal to
or better than the MCID (5-point improvement from
baseline) in SF-36 bodily pain domain score [19]; pro-
portion of patients reporting EuroQoL 5-Dimension
3-Level Questionnaire (EQ-5D-3 L) pain item scores
of no, moderate, or extreme pain/discomfort; and
correlation coefficients for changes from baseline be-
tween pain scores.
Statistical methods
Mean changes from baseline in the pain VAS and SF-36
bodily pain domain scores were analyzed using a mixed-
effect model for repeated measures (MMRM) through
week 24 with treatment regimen, analysis visit, and
randomization stratum (TNF-naive or TNF-IR) as fac-
tors, weight and baseline score as continuous covariates,
and treatment by analysis visit and baseline score by
analysis visit as interaction terms, and an unstructured
covariance structure. Mean changes from baseline were
reported as observed starting from week 28. Frequencies
of patient EQ-5D-3 L pain/discomfort domain response
were reported using observed data up to week 104. Cor-
relation with pain measures was analyzed using Pear-
son’s correlation coefficient and P values were calculated
using the chi-square likelihood ratio test. The proportion
of patients with VAS improvement ≥ 20% were reported
using as-observed data and P values were calculated
using Fisher’s exact test. The proportion of patients with
improvement ≥ 5 in the SF-36 bodily pain domain score
were reported using as-observed data and P values were
calculated using Fisher’s exact test. Pre-specified sub-
group analyses (TNF-naïve and TNF-IR) were performed
using MMRM through week 24 and data were reported
as observed starting from week 28. Only the results for
patients receiving the approved doses – secukinumab
300 mg and secukinumab 150 mg – are reported in this
article. Due to the re-randomization of patients in the
placebo group at week 16, statistical comparisons of
secukinumab versus placebo are presented up to week
16. Analyses were exploratory in nature and conducted
without adjustment for multiple comparisons.
Results
Study population
Overall, 397 patients with active PsA were randomized
for this trial. Demographics and baseline diseasecharacteristics have been previously reported for patients in
this study and are presented in Additional file 1: Table S1.
In the overall patient population, mean pain VAS scores
were in the range of 55.4–58.9 and mean SF-36 bodily pain
scores were in the range of 33.7–37.6. Further, 99% of pa-
tients reported moderate-to-extreme pain or discomfort at
baseline measured by the EQ-5D-3 L pain/discomfort item.
Of 298 patients, 193 (65%) were TNFi naïve at baseline.
Efficacy
Treatment with secukinumab was associated with rapid
and sustained relief of pain in patients with PsA. Signifi-
cant improvements in mean changes from baseline in pain
VAS scores were reported beginning at week 3 compared
with placebo (− 5.8) with secukinumab 300 mg (−16.9;
P < 0.0001) and secukinumab 150 mg (−12.6; P < 0.05).
Improvements in mean changes from baseline in pain
VAS scores continued to week 16 and were sustained to
week 104 with both doses of secukinumab (Fig. 1a). Add-
itionally, most patients treated with secukinumab reported
responses equal to or better than the MCID in the pain
VAS response. At week 3, a significantly greater number
of patients receiving secukinumab 300 mg had ≥ 20% im-
provement in pain VAS response compared with placebo
(60.6% vs 36.6%; P < 0.01). For both doses of secukinumab,
the proportion of patients with improvements equal to or
better than the MCID in pain VAS scores continued to
increase to week 16 and similar levels of attainment were
reported at week 104 (Fig. 1b).
A similar trend for reductions in patient-reported pain
with secukinumab was reported for SF-36 bodily pain
domain scores. At week 4, mean changes from baseline
in SF-36 bodily pain scores were significantly greater
with both secukinumab 300 mg (16.2) and secukinumab
150 mg (16.3) compared with placebo (5.9; P < 0.0001
for both). Continued improvement in SF-36 bodily pain
domain scores were reported up to week 12 with both
secukinumab doses, and initial improvements were sus-
tained to week 104 for both secukinumab doses (Fig. 2a).
Most patients treated with secukinumab also reported equal
to or better than the MCID in the SF-36 bodily pain domain
score. At week 4, a significantly greater number of patients
receiving secukinumab 300 mg (72.3%) and secukinumab
150 mg (73.7%) had improvements ≥ 5 points in SF-36 bod-
ily pain domain score compared with placebo (46.9%;
P < 0.001 for both). For both doses of secukinumab, the
proportion of patients with improvements equal to or better
than the MCID in SF-36 bodily pain domain scores were
maintained to week 104 (Fig. 2b). The MCID for SF-36 bod-
ily pain domain scores was attained in both anti-TNF-naive
and anti-TNF-IR patients receiving secukinumab.
At baseline, only 1% of patients reported no pain or
discomfort in the EQ-5D-3 L pain/discomfort item. Fol-
lowing 4 weeks of secukinumab treatment, no pain or
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Fig. 1 Proportion of patients with ≥ 20% improvement in pain visual analog scale (VAS) score through week 104 (a) and proportion of patients
with ≥ 20% improvement in pain VAS response (b)
Data are presented as LS mean change using MMRM from weeks 1-24, and observed data are presented from weeks 28-104 (shaded area);
P values are calculated from a MMRM analysis (a). Observed data are presented; P values are calculated from Fisher’s exact test (b)
1Number of patients originally randomized to each treatment group. *P < 0.0001; †P < 0.001; ‡P < 0.05 §P < 0.01 versus placebo
LS, least squares; MMRM, mixed-effect model for repeated measures; PBO, placebo; s.c., subcutaneous; SEC, secukinumab
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secukinumab 300 mg, 9.1% of patients receiving
secukinumab 150 mg, and 5.2% of patients receiving
placebo (Fig. 3). With secukinumab treatment, the pro-
portion of patients reporting no pain or discomfort
continued to increase over time, especially with
secukinumab 300 mg and after 2 years of treatment
with secukinumab 300 mg almost 30% of patients ex-
perienced no pain or discomfort by EQ-5D-3 L.
At weeks 16, 24, 52, and 104, improvements from base-
line in mean pain VAS scores were significantly correlated
with improvements from baseline in mean SF-36 bodily
pain scores (correlation coefficients of − 0.56 to − 0.62;
P < 0.01 for all) and EQ-5D pain/discomfort domain
scores (correlation coefficients of 0.36 to 0.47; P < 0.01
for all). Similarly, improvements from baseline in meanSF-36 bodily pain scores were significantly correlated
with improvements in EQ-5D pain/discomfort domain
scores at weeks 16, 24, 52, and 104 (correlation coeffi-
cients of − 0.45 to − 0.52; P < 0.01 for all).
Response by prior TNF inadequate response
TNF-naive and TNF-IR patients both demonstrated
significant improvements in mean changes from baseline
in pain VAS scores and SF-36 bodily pain scores.
TNF-naïve patients receiving secukinumab 300 mg re-
ported significant improvements in mean change from
baseline in pain VAS score compared with placebo begin-
ning at week 3 (− 19.7 vs − 8.5; P < 0.01). With both doses
of secukinumab, improvements continued to week 104
(Table 1). Although a similar trend was observed in
TNF-IR patients, the magnitude of improvements was
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Fig. 2 Change from baseline in the Short Form-36 (SF-36) bodily pain score through week 104 (a) and proportion of patients with improvement ≥ 5
in the SF-36 bodily pain domain score (b)
Data are presented as LS mean change using MMRM from weeks 1-24, and observed data are presented from weeks 52-104 (shaded area); P values
are calculated from a MMRM analysis (a). Observed data are presented; P values are calculated from Fisher’s exact test (b)
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Table 1 Effect of secukinumab on pain by prior TNF exposure through week 104
Week 3 Week 4 Week 8 Week 16 Week 24 Week 52 Week 104
TNF-naïve
Pain VAS, mean change from baselinea
Secukinumab 300 mg −19.7* −20.7** − 20.7* −27.8**** − 24.0 −30.3 −29.6
Secukinumab 150 mg −12.8 −15.2 −21.8* − 25.1*** −26.3 −28.1 −28.3
Placebo −8.5 −11.3 −10.1 −11.3 – – –
SF-36 bodily pain, mean change from baselineb
Secukinumab 300 mg – 18.4**** 18.2* 23.8**** 23.9 24.4 24.2
Secukinumab 150 mg – 18.9**** 20.0*** 25.4**** 25.7 25.8 22.2
Placebo – 5.6 7.3 8.6 – – –
EQ-5D-3 L, no pain or discomfortc
Secukinumab 300 mg – – – 21.5% 24.6% 28.6% 32.8%
Secukinumab 150 mg – – – 22.2% 14.8% 20.3% 17.0%
Placebo – – – 6.9% – – –
TNF-IR
Pain VAS, mean change from baselined
Secukinumab 300 mg −13.1** −14.9 −16.8** −18.2** −20.7 −22.5 −19.3
Secukinumab 150 mg −14.8* −21.3* −21.2* −21.1* − 20.0 −23.9 − 20.4
Placebo −2.1 −5.9 −3.4 −4.4 – – –
SF-36 bodily pain, mean change from baselinee
Secukinumab 300 mg – 15.1 18.7* 18.3* 23.6 23.0 24.5
Secukinumab 150 mg – 13.6 21.0*** 17.9* 16.0 19.0 14.0
Placebo – 7.8 5.7 5.2 – – –
EQ-5D-3 L, no pain or discomfortf
Secukinumab 300 mg – – – 12.5% 12.5% 15.6% 17.2%
Secukinumab 150 mg – – – 10.8% 5.9% 20.0% 12.5%
Placebo – – – 3.3% – – –
Least squares mean change using a mixed-effect model for repeated measures (MMRM) from weeks 1 to 24, and observed data from weeks 52 to 104, for pain
visual analog scale (VAS) and Short Form-36 (SF-36) bodily pain scores. Observed data are presented for the EuroQoL 5-Dimension 3-Level Questionnaire (EQ-5D-3 L). At
week 16, patients initially randomized to placebo who were non-responders switched to secukinumab treatment. Results are not shown for patients who continued on
placebo after week 16. Data are presented only for evaluable patients at each time point. TNF-naïve patients originally randomized to secukinumab 300 mg= 67, to
secukinumab 150 mg= 63, and to placebo = 63; patients with inadequate response to TNF (TNF-IR) originally randomized to secukinumab 300 mg= 33, to secukinumab
150 mg= 37, and to placebo = 35. P values were calculated from a MMRM analysis
aNumber of evaluable patients, week 52: 59 for secukinumab 300 mg and 150 mg; week 104: 57 for secukinumab 300 mg and 53 for secukinumab 150 mg
bNumber of evaluable patients, week 52: 62 for secukinumab 300 mg and 59 for secukinumab 150 mg; week 104: 57 for secukinumab 300 mg and 53 for
secukinumab 150 mg
cNumber of evaluable patients, week 52: 63 for secukinumab 300 mg and 59 for secukinumab 150 mg; week 104: 58 for secukinumab 300 mg and 53 for
secukinumab 150 mg
dNumber of evaluable patients, week 52: 30 for secukinumab 300 mg and 29 for secukinumab 150 mg; week 104: 29 for secukinumab 300 mg and 24 for
secukinumab 150 mg
eNumber of evaluable patients, week 52: 32 for secukinumab 300 mg and 30 for secukinumab 150 mg; week 104: 29 for secukinumab 300 mg and 26 for
secukinumab 150 mg
fNumber of evaluable patients, week 52: 32 for secukinumab 300 mg and 30 for secukinumab 150 mg; week 104: 29 for secukinumab 300 mg and 24 for
secukinumab 150 mg
*P < 0.01; **P < 0.05; ***P < 0.001; ****P < 0.0001, versus placebo. TNF, tumor necrosis factor
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provements from baseline in pain VAS scores were reported
at week 3 with secukinumab 300 mg (− 13.1; P < 0.05 vs
placebo) and secukinumab 150 mg (− 14.8; P < 0.01 vs
placebo). Due to the smaller number of TNF-IR patients
there was more volatility in responses over time. Nonethe-
less, improvements were maintained over time.Significant mean improvements from baseline in
SF-36 bodily pain scores were also reported by both
TNF-naive and TNF-IR patients receiving secukinumab
(Table 1). At week 4, mean changes from baseline in
SF-36 bodily pain scores in TNF-naïve patients im-
proved by 18.4 with secukinumab 300 mg, by 18.9
with secukinumab 150 mg compared with 5.6 for
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time, the degrees of improvement in SF-36 bodily
pain scores were similar with both doses of secukinumab
in TNF-naïve patients. In TNF-IR patients, there were
significant mean improvements from baseline in SF-36
bodily pain scores at week 8 with both secukinumab
300 mg (18.7; P < 0.01) and 150 mg (21.0; P < 0.001) com-
pared to 5.7 with placebo. Mean changes from baseline in
SF-36 bodily pain scores were similar over time between
TNF-naive and TNF-IR patients with secukinumab 300 mg.
Both TNF-naive and TNF-IR patients also reported
improvements in the EQ-5D-3 L pain item scores. At
week 16, 22% of TNF-naive patients receiving either
dose of secukinumab reported no pain or discomfort
compared with 6.9% of patients receiving placebo
(Table 1). The proportion of TNF-naive patients re-
ceiving secukinumab 300 mg that reported no pain or
discomfort continued to increase to week 104 when
32.8% TNF-naive patients had no pain or discomfort.
A similar trend was observed in TNF-IR patients but
fewer of these patients reported no pain or discom-
fort compared with TNF-naïve patients. There was a
small numerical increase in the number of TNF-IR
patients reporting no pain or discomfort at week 104.
Discussion
Pain is one of the most important domains affecting
HRQoL in patients with PsA [7], and patients with
PsA report role limitations caused by both emotional
problems and bodily pain [5, 20]. Pain has also been
linked to fatigue in other inflammatory arthritides
[21]. Additionally, joint pain has a quantifiable burden
to society as demonstrated by work limitations in pa-
tients with PsA [22]. Taken together, these findings
exemplify the importance of managing pain when
treating patients with PsA.
In this post-hoc analysis of the phase-3, FUTURE 2
study, secukinumab 300 mg and secukinumab 150 mg
both provided rapid and sustained pain relief to pa-
tients with PsA over 2 years’ treatment. Improve-
ments in pain with secukinumab were consistent
across three different patient-reported measures (pain
VAS, SF-36 bodily pain, and EQ-5D-3 L pain/discom-
fort) and were observed regardless of prior exposure
to TNFis. Improvements in pain reported in this trial
are consistent with findings of improved pain and
HRQoL in other secukinumab trials. In FUTURE 1,
improvement was observed in both mean pain VAS
and SF-36 bodily pain domain scores [19]. Further,
secukinumab 150 mg demonstrated sustained improve-
ment in HRQoL with an SF-36 physical component sum-
mary score of 4.89 at week 104 [17]. In FUTURE 2,
improved physical function was reported at week 24
with a change from baseline in the Health AssessmentQuestionnaire Disability Index (HAQ-DI) of − 0.56 with
secukinumab 300 mg (P = 0.004 vs placebo) and − 0.48
with secukinumab 150 mg (P = 0.0555 vs placebo) [15].
In this trial, improvements in pain with secukinumab
treatment were sufficient to meet or exceed established
definitions for MCID in pain for PsA and were observed
irrespective of previous exposure to TNFis. Due to the
level of improvement in pain with secukinumab treat-
ment, it is interesting to consider whether pain allevi-
ation is due to overall improvement in inflammation or
through a direct role of IL-17 inhibition. Plasma levels
of IL-17A are elevated in patients with fibromyalgia and
in mice, IL-17 contributes to neuroinflammatory re-
sponses and pain hypersensitivity following neuropathic
injury [23, 24]. These findings suggest that additional in-
vestigation is warranted on the role of IL-17 in other
conditions associated with pain such as PsA.
There was significant correlation between the improve-
ment from baseline in mean pain VAS scores and mean
SF-36 bodily pain scores and EQ-5D pain/discomfort
domain scores and significant correlation between im-
provement from baseline in mean SF-36 bodily pain
scores and EQ-5D pain/discomfort scores. Together these
correlations indicate that secukinumab consistently im-
proves pain regardless of the specific measurement used
for assessment.
Secukinumab 300 mg and secukinumab 150 mg also
improved pain in both TNF-naive and TNF-IR pa-
tients measured by the pain VAS, SF-36 bodily pain
scores, and EQ-5D-3 L pain/discomfort domain. Not
surprisingly, TNF-naïve patients reported numerically
greater changes from baseline in all three pain out-
comes than those reported by TNF-IR patients.
Limitations of this study include that it was a post-hoc
analysis, the lack of an active comparator, and lack of
placebo control after week 24.
Conclusions
Secukinumab has previously demonstrated efficacy in
treatment of the signs and symptoms of PsA, inhibition of
radiographic progression in patients with PsA, and a fa-
vorable safety profile [15–17]. In this study, secukinumab
provided rapid pain relief for patients with PsA as assessed
by multiple clinically relevant patient-reported pain
measures. Pain relief began as early as week 3 and im-
provements were sustained through 104 weeks. Further,
improvements in pain were reported by patients regard-
less of prior exposure to TNFis.Additional file
Additional file 1: Table S1. Baseline demographics and disease severity
characteristics. (DOCX 13 kb)
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